Sugi Predict

Sugi Predict / Compounds / SCHEMBL4529161

SCHEMBL4529161

SCHEMBL4529161

CCNS(=O)(=O)c1ccccc1Br

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.66
▸ POLB P06746 3/20 0.55
▸ PLCG1 P19174 1/20 0.52
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ CA4 P22748 1/20 0.50
▸ CA6 P23280 1/20 0.50
▸ GLA P06280 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ CA12 O43570 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ EDNRA P25101 2/20 0.45
▸ EDNRB P24530 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9577180 0.85 RECQL (0.50) RECQLPOLBPLCG1CA1CA2
SCHEMBL21089221 0.85 RECQL (0.77) RECQLPOLBPLCG1CA1CA2
SCHEMBL2229994 0.82 RECQL (0.88) RECQLPOLBPLCG1CA1CA2
SCHEMBL2227866 0.80 RECQL (0.56) RECQLPOLBPLCG1CA1CA2
SCHEMBL15915560 0.79 RECQL (0.55) RECQLPOLBPLCG1CA1CA2
SCHEMBL18706689 0.79 RECQL (0.55) RECQLPOLBPLCG1CA1CA2
SCHEMBL30194714 0.78 PKM (0.53) MAPTCA12CA9EDNRAALDH1A1
SCHEMBL126986 0.78 PKM (0.53) MAPTCA12CA9EDNRAALDH1A1
SCHEMBL13469361 0.78 CA12 (0.47) RECQLGLASMN1; SMN2CA12CA9
SCHEMBL28885334 0.78 KMT2A (0.68) RECQLPOLBCA2GLAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683269-B2 2-cyanoisoindoline derivatives for treating cancer MISSION THERAPEUTICS LIMITED (GB) 2020-06-16 — — US disclosed
EP-3495359-A1 FLAP MODULATORS Janssen Pharmaceutica NV (BE) 2019-06-12 — — EP disclosed
US-20190010122-A1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LIMITED (GB) 2019-01-10 — — US disclosed
EP-3070085-B1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-01-09 — — EP disclosed
EP-2951170-B1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-10-24 — — EP disclosed
EP-2714677-B1 PYRIDINE-AND PYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2018-08-22 — — EP disclosed
US-9884878-B2 FLAP modulators JANSSEN PHARMACEUTICA NV (BE) 2018-02-06 — — US disclosed
US-9884878-B2 FLAP modulators JANSSEN PHARMACEUTICA NV (BE) 2018-02-06 — — US disclosed
US-9884878-B2 FLAP modulators JANSSEN PHARMACEUTICA NV (BE) 2018-02-06 — — US disclosed
US-9745328-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2017-08-29 — — US disclosed
US-9079866-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2015-07-14 — — US disclosed
US-9079866-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2015-07-14 — — US disclosed
US-20140221311-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 — — US disclosed
US-20140221311-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 — — US disclosed
US-20140221311-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 — — US disclosed
US-20140142097-A1 PYRIDINE-AND PYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2014-05-22 — — US disclosed
WO-2012161877-A1 PYRIDINE-AND PYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-11-29 — — WO disclosed
US-20100035823-A1 LIGANDS OF SH3 DOMAINS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2010-02-11 — — US disclosed
US-20090105477-A1 Quinazoline Protein Tyrosine Phosphatase Inhibitors BERTHEL STEVEN JOSEPH 2009-04-23 — — US disclosed
US-20060211715-A1 Quinazoline protein tyrosine phosphatase inhibitors BERTHEL STEVEN J 2006-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190010122-A1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER USP7, USP47, USP2 RECQL 322/4885POLB 2038/4885PLCG1 3595/4885
US-20090105477-A1 Quinazoline Protein Tyrosine Phosphatase Inhibitors PTPN5, PTPN1, PTPN7 RECQL 1079/4885POLB 3533/4885PLCG1 1069/4885
US-20100035823-A1 LIGANDS OF SH3 DOMAINS PACSIN2, NCK1, UBASH3B RECQL 3782/4885POLB 4394/4885PLCG1 2434/4885
US-20060211715-A1 Quinazoline protein tyrosine phosphatase inhibitors PTPN5, PTPN1, PTPN7 RECQL 1079/4885POLB 3533/4885PLCG1 1069/4885
US-10683269-B2 2-cyanoisoindoline derivatives for treating cancer USP7, USP47, USP2 RECQL 322/4885POLB 2038/4885PLCG1 3595/4885
US-20140142097-A1 PYRIDINE-AND PYRAZINE DERIVATIVES TBK1, IRAK1, IRAK2 RECQL 258/4885POLB 1262/4885PLCG1 1592/4885
US-20140221311-A1 FLAP MODULATORS PGF, FEN1, TBXA2R RECQL 254/4885POLB 1233/4885PLCG1 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.